FDA used ‘critically flawed’ risk-benefit analysis to ‘justify’ COVID vaccines for children

The U.S. Food and Drug Administration relied on a critically flawed risk-benefit assessment to authorize emergency use of Pfizer’s COVID-19 vaccine for children 5-11 years of age.